View on Pubmed.gov 31045582 | View on doi.org 10.1172/jci.ins...
Complement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2.
- School of Biomedical Sciences, Faculty of Medicine.
- Blood and Bone Diseases Program, Mater Research Institute.
- School of Public Health, Faculty of Medicine, and.
- Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, Australia.
- Orthopaedic Department, Princess Alexandra Hospital, Brisbane, Australia.
- Princess Alexandra Hospital - Southside Clinical School, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
- Antigen Presentation and Immunoregulation Laboratory, QIMR Berghofer Medical Research Institute, Brisbane Australia.
- Trauma, Critical Care and Recovery, Brisbane Diamantina Health Partners, Brisbane, Australia.
Abstract
Traumatic spinal cord injury (SCI) triggers an acute-phase response that leads to systemic inflammation and rapid mobilization of bone marrow (BM) neutrophils into the blood. These mobilized neutrophils then accumulate in visceral organs and the injured spinal cord where they cause inflammatory tissue damage. The receptor for complement activation product 3a, C3aR1, has been implicated in negatively regulating the BM neutrophil response to tissue injury. However, the mechanism via which C3aR1 controls BM neutrophil mobilization, and also its influence over SCI outcomes, are unknown. Here, we show that the C3a/C3aR1 axis exerts neuroprotection in SCI by acting as a physiological antagonist against neutrophil chemotactic signals. We show that C3aR1 engages phosphatase and tensin homolog (PTEN), a negative regulator of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, to restrain C-X-C chemokine receptor type 2-driven BM neutrophil mobilization following trauma. These findings are of direct clinical significance as lower circulating neutrophil numbers at presentation were identified as a marker for improved recovery in human SCI. Our work thus identifies C3aR1 and its downstream intermediary, PTEN, as therapeutic targets to broadly inhibit neutrophil mobilization/recruitment following tissue injury and reduce inflammatory pathology.
References
Glia. 1999 May;26(3):201-11
Science. 2000 Feb 11;287(5455):1049-53
Mol Cell Biol. 2000 Jun;20(11):4106-14
J Immunol. 2000 Nov 15;165(10):5406-9
Cited by 77 citations (total)
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't
Prognostic value of early leukocyte fluctuations for recovery from traumatic spinal cord injury.
Electronic publication date January 20, 2021
Trisha Jogia [...] Marc J Ruitenberg et al.
BACKGROUND
Acute traumatic spinal cord injury (SCI) induces a systemic immune response involving circulating white blood cells (WBCs). How this response...
Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural
Molecular basis of anaphylatoxin binding, activation, and signaling bias at complement receptors.
Electronic publication date October 30, 2023
Manish K Yadav [...] Cornelius Gati et al.
The complement system is a critical part of our innate immune response, and the terminal products of this cascade, anaphylatoxins...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
Substances
- •
- •
- •
- •
- •
- •